SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC
Trial Parameters
Brief Summary
To explore the safety and efficacy of neoadjuvant therapy for locally advanced rectal cancer with short course radiotherapy followed by camrelizumab combined with fluzoparib and chemotherapy
Eligibility Criteria
Inclusion Criteria: 1. Patients who provided written informed consent form for participation in this study; 2. Aged 18-75 years old, male or female; 3. Histologically confirmed pathological diagnosis of proficient mismatch repair/microsatellite stable(pMMR/MSS) rectal adenocarcinoma; 4. The lower margin of the tumor is ≤10cm from the anal verge; 5. Clinical Stage (according to the 8th edition of AJCC) T3NanyM0 and confirmed on imaging to fulfil at least any of the following: （1）MRF (+)，（2）EMVI（+），（3）LPLN（+）；or T4NanyM0 with or without one of the above three; 6. Those who are expected to achieve R0 resection; 7. Able to swallow tablets normally; 8. Patients with the ECOG performance status of 0 or 1 at the time of enrollment; 9. Patients have not received any previous anti-tumor therapy for rectal cancer; 10. Planning to undergo surgery after completion of neoadjuvant therapy; 11. Have no contraindications to surgery; 12. Normal function of major organs, including: 1. Routine blood test